India’s First Dengue Vaccine Trial Nearly Completed

• The Indian Council of Medical Research (ICMR) and Panacea Biotec Ltd. have initiated third phase trials for India’s first dengue vaccine.

• About 8,000 out of the targeted 10,000 participants have enrolled in the trials.

• The trial will be conducted at 20 centers across India.

• The trial is primarily funded by ICMR, with partial support from Panacea Biotec.

• The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.

• The tetravalent dengue vaccine strain (TV003/TV005), developed by the National Institutes of Health, has shown promising results in preclinical and clinical trials worldwide.

• Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of developing a vaccine.

• Dengue is a major public health concern in India, with over 129 countries reporting dengue viral disease by the end of 2023.